Characteristics of US adults with the metabolic syndrome and therapeutic implications

Diabetes, Obesity and Metabolism

Volumn 6, Issue 5, 2004, Pages 353-362

  Jacobson, T A ^a   Case, C C ^b   Roberts, S ^c   Buckley, A ^c   Murtaugh, K M ^d   Sung, J C Y ^e   Gause, D ^e   Varas, C ^f   Ballantyne, Christie ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Pharmaceutical Product Development   (United States)

^d Reliant Pharmaceuticals LLC   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Novartis Global Epedemiology   (Spain)

Author keywords

Drug therapy; Metabolic syndrome; Treatment guidelines

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUTRITIONAL PARAMETERS; OBESITY; POPULATION DISTRIBUTION; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 4444348746     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00354.x     Document Type: Article

References (37)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-1109.
3. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
4. McNeill AM, Rosamond W, Ballantyne C. Prevalence of the metabolic syndrome and its association with incident coronary heart disease. Presented at the NHLBI Training Session in conjunction with the 42nd Annual AHA Conference on Cardiovascular Epidemiology and Prevention, Honolulu, Hawaii, April 23, 2002.
5. Lindblad U, Langer RD, Wingard DL, Thomas RG, Barrett-Connor EL. Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol 2001; 153: 481-499.
6. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
7. National Center for Health Statistics. Health, United States, 2001. Hyattsville, MD: Centers for Disease Control and Prevention, 2001.
8. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics Fact Sheet. Bethesda, MD: National Diabetes Information Clearinghouse, 1999.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
11. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: U.S. Department of Health and Human Services, 1994.
12. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JCY, Ballantyne CM. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering drug therapy based on updated NHANES III data. Arch Intern Med 2000; 160: 1361-1369.
13. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control - National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-135.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. Frohlich ED, Grim C, Labarthe DR, Maxwell MH, Perloff D, Weidman WH. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the steering committee, American Heart Association. Hypertension 1988; 11: 210A-221A.
16. National Health and Nutrition Examination Survey III. Body Measurements (Anthropometry). Rockville, MD: Westat, Inc., 1988.
17. Mohadjer L, Montaquila J, Waksberg J et al. National Health and Nutrition Examination Survey III. Weighting and Estimation Methodology: Executive Summary. Hyattsville. Md: National Center for Health Statistics 1996.
18. Hunt ME, O'Malley PG, Feuerstein I, Taylor AJ. The metabolic score predicts subclinical atherosclerosis independent of fasting serum LDL: evidence supporting inclusion of the metabolic syndrome as a component within the NCEP ATP III guidelines. J Am Coll Cardiol 2002; 39: 262A [Abstract 1179-77].
19. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25-44.
20. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992; 20: 38-45.
21. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 1997; 46: 1594-1600.
22. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001; 24: 1758-1763.
23. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105: 2696-2698.
24. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
26. Serruys PW, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215-3222.
27. Rubins HB, Robins SJ, Collins D et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
28. Rubins HB, Robins SJ, Collins D et al. for the VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
29. National Institutes of Health. National Heart, Lung, and Blood Institute in cooperation with National Institute of Diabetes and Digestive and Kidney Diseases. Obesity Education Initiative. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 98-4083. Bethesda, MD: National Institutes of Health, 1998.
30. Tuomilehto J, Lindstrom J, Eriksson JG et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
31. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
32. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37-45.
33. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-27.
34. Ballantyne CM, Olsson AG, Cook TJ et al. for the Scandinavian Simvastatin Survival (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-3051.
35. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
36. Zhao X-Q, Morse J, Chait A et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 2002; 39: 242A [Abstract 1130-73].
37. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540 [Letter].